Prime-Boost BCG Vaccine

Award type :
Product Development Award

Product type :
Vaccines

Award year :
2020

Project start date :
07 / 01 / 2020

Project end date :
12 / 30 / 2024

Project duration (months) :
36

Development stage :
Preclinical

Target disease :
Tuberculosis

Region served :
Low- and Middle-Income Countries

Recipient organization / Country of funding recipient organization :
Chungnam Univ. / Republic of Korea

Collaborator(s) / Country :
University-Industry Foundation, Yonsei University Health System / Republic of Korea, Institut Pasteur / France, Quratis / Republic of Korea

Funding amount(KRW) :
1,557,500,000

The Bacillus Calmette–Guérin (BCG) vaccine is widely used; however, it provides insufficient protection against tuberculosis (TB). This project aims to develop a prime-boost vaccine strategy that enhances the initial immune response and strengthens the adaptive immune response. This BCG prime-boost regimen consists of an ESX-1Mmar vaccine for priming and a multi-antigenic Rv2299c-ESAT-6 vaccine with a GLA-SE/c-di-GMP adjuvant system for boosting. Chungnam National University College of Medicine is working on the pre-clinical development stage, which includes the evaluation of antigenic properties, immunogenicity, and efficacy test. The work is being done in collaboration with Yonsei University College of Medicine, Quratis and Institut Pasteur. This vaccine strategy has the potential to impact TB control and complement other TB vaccine candidates.